QNCX
Quince Therapeutics, Inc.
NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY
$1.31
+6.50% today
Updated 2026-04-30
Market cap
$20.05M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-16.80
Dividend yield
—
52W range
$1 – $46
Volume
63.6M
Quince Therapeutics, Inc. (QNCX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $7.72M | $72.88M | $124.37M | $189.47M | $133.23M | $103.91M | $180.20M | $114.48M |
| Cash & equivalents | $7.34M | $24.87M | $51.21M | $66.84M | $69.72M | $44.58M | $20.75M | $6.21M |
| Current assets | $7.54M | $72.58M | $106.06M | $137.86M | $111.67M | $93.75M | $77.44M | $44.04M |
| Total liabilities | $28.00M | $1.46M | $8.89M | $17.20M | $14.64M | $3.32M | $95.12M | $84.33M |
| Current liabilities | $1.76M | $1.46M | $8.89M | $17.00M | $14.22M | $3.07M | $9.57M | $7.28M |
| Long-term debt | — | — | — | — | — | — | $13.43M | $14.32M |
| Shareholder equity | $-20.28M | $71.42M | $115.48M | $172.26M | $118.59M | $100.59M | $85.08M | $30.15M |
| Retained earnings | $-20.35M | $-32.83M | $-69.81M | $-146.65M | $-236.60M | $-288.26M | $-319.64M | $-376.47M |
| Accounts receivable | — | — | — | — | $1.13M | $1.00M | $993000.00 | $882000.00 |
| Inventory | — | — | — | — | $2.25M | $2.29M | — | — |
| Goodwill | — | — | — | — | — | $0.00 | $17.63M | $0.00 |